Transjugular retrograde obliteration for chronic portosystemic encephalopathy.
Chronic portosystemic encephalopathy (CPSE) is uncommon, and its management has yet to be determined. We have been able to control five cases of CPSE using transjugular retrograde obliteration (TJO), and we report our clinical results with this technique. All of the five patients were suffering from cirrhosis and had gastric varices and large gastrorenal shunts. According to Sherlock's classification, the grade of encephalopathy was II in two patients, III in two, and IV in one. According to Child's classification, one had class B and four had class C cirrhosis. TJO was performed using a 6-F angiographic catheter with an occlusive balloon 20 mm in diameter. Absolute ethanol and 5% ethanolamine oleate with iopamidol were used to obliterate the gastrorenal shunt. The gastrorenal shunt was successfully obliterated, and the encephalopathy improved to grade 0 after TJO in all cases. The portal flow volume increased significantly from 542 +/- 189 to 992 +/- 139 mL/min (p < 0.01). The plasma ammonia levels before and after TJO were 189 +/- 40 and 51 +/- 23 microg/dL, and the indocyanine green retention rates at 15 min were 44 +/- 13% and 27 +/- 12%, with both changes being significant (p < 0.01). Minor complications observed were fever of over 38 degrees C and tarry stools due to hemorrhagic gastritis in one patient, which was being controlled conservatively. One patient died of hepatocellular carcinoma 27 months after TJO. The other four patients survived without recurrence of CPSE 17-74 months (44 +/- 24 months) after TJO. We conclude that TJO can be adopted as a safe and effective treatment for CPSE.
Chikamori
F
F
Department of Surgery, Kuniyoshi Hospital, 1-3-4 Kamimachi, Kochi City, Kochi 780-0901, Japan.
Kuniyoshi
N
N
Shibuya
S
S
Takase
Y
Y
D000368:Aged; D021721:Balloon Occlusion / Q000379:methods; D002908:Chronic Disease; D004932:Esophageal and Gastric Varices / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D006501:Hepatic Encephalopathy / Q000150:complications / Q000628:therapy*; D006801:Humans; D007601:Jugular Veins; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000008:administration & dosage; D012082:Renal Veins; D012597:Sclerosing Solutions / Q000008:administration & dosage; D015911:Sclerotherapy; D013270:Stomach / Q000098:blood supply*; D014057:Tomography, X-Ray Computed
D009829:Oleic Acids; D012597:Sclerosing Solutions; D000431:Ethanol; C033343:ethanolamine oleate